- Results from a Phase 1 single and multiple ascending-dose clinical trial evaluating Lexicon Pharmaceuticals ' (LXRX -0.7%) LX2761 in healthy volunteers and type 2 diabetics showed encouraging action.
- In patients with type 2 diabetes who were washed off metformin for three days prior to dosing, LX2761, a gastrointestinal (GI) tract-selective SGLT1 inhibitor, showed minimal absorption and no systemic effect and no increase in urine glucose excretion from baseline. It also reduced postprandial (after a meal) glucose while increasing plasma levels of blood glucose-lowering GLP-1.
- On the safety front, the most common treatment-related and dose-limiting adverse event was diarrhea which the company says is consistent with the SGLT1 mechanism of action which reduces glucose absorption in the gut.
- LX2761 is designed to inhibit SGLT1, a protein that plays a key role in glucose reabsorption, in the GI tract without significantly inhibiting SGLT2 in the kidney.
- Sanofi (PA:SASY) (SNY +0.5%) has certain rights of first negotiation for future development and commercialization of the candidate.
- Now read: Conatus: A Rare Investment For Opportunistic Investors
Original article